eNOS4 polymorphism of the endothelial nitric oxide synthase predicts risk for severe diabetic retinopathy

Author(s): Taverna MJ, Sola A, Guyot-Argenton C, Pacher N, Bruzzo F, et al.

Abstract

Background: Genetic factors may be involved in the development, and particularly in the severity, of diabetic retinopathy (DR), in addition to chronic hyperglycaemia. Increased nitric oxide generation has been suggested to play a significant role in the pathogenesis of DR.

Aims and methods: To examine whether the eNOS4 is involved in the risk of severe DR, 200 unrelated Caucasian Type 1 diabetic patients of long duration were randomly selected (M/F 103/97, age 44.4 +/- 12.4 years, diabetes duration 27.7 +/- 10.0 years, body mass index 24.3 +/- 3.4 kg/m2, HbA1c 8.6 +/- 1.3%). The eNOS4 polymorphism was analysed by polymerase chain reaction, and DR by retinal angiography and classified as presence (n = 101) or absence (n = 99) of severe (proliferative or pre-proliferative) DR.

Results: The genotype distribution of eNOS4b/b (wild-type), eNOS4b/a (heterozygous) and eNOS4a/a (homozygous) was 72%, 24.5% and 3.5%, respectively. Frequency of eNOS4a/a was significantly lower in patients with severe DR (n = 0) when compared with controls (n = 7, odds ratio (OR) = 0 (95% confidence interval (CI) = 0.5-0.74), P = 0.02). eNOS4b/b was more frequent in patients with severe DR (n = 80) when compared with controls (n = 64, OR = 2.1 (95% CI = 1.1-4.12), P = 0.032). Frequency of eNOS4b/a was not different between the study (n = 21) and control groups (n = 28, ns). The allelic frequencies between the study and control groups were different (4b: n = 181 vs. n = 156, respectively, OR = 2.3 (95% CI = 1.27-4.25), P = 0.005; 4a: n = 21 vs. n = 42, respectively, OR = 0.4 (95% CI = 0.24-0.79), P = 0.005).

Conclusions: We demonstrate in Caucasians with Type 1 diabetes that (i) eNOS4a/a is associated with absent or non-severe DR, and (ii) eNOS4b/b is associated with severe DR.

Similar Articles

Costs and duration of care for lower extremity ulcers in patients with diabetes

Author(s): Holzer SE, Camerota A, Martens L, Cuerdon T, Crystal-Peters J, et al.

The L-arginine-nitric oxide pathway

Author(s): Moncada S, Higgs A

Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy

Author(s): Nakagawa T, Sato W, Glushakova O, Heinig M, Clarke T, et al.

eNOS gene polymorphism association with retinopathy in type 1 diabetes

Author(s): Bazzaz JT, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, et al.

Endothelial nitric oxide synthase VNTR (intron 4 a/b) polymorphism association with type 2 diabetes and its chronic complications

Author(s): Mehrab-Mohseni M, Tabatabaei-Malazy O, Hasani-Ranjbar S, Amiri P, Kouroshnia A, et al.

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Author(s): Wild S, Roglic G, Green A, Sicree R, King H

Ethnic India: a genomic view, with special reference to peopling and structure

Author(s): Basu A, Mukherjee N, Roy S, Sengupta S, Banerjee S, et al.

Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians

Author(s): Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Sud K, et al.

Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction

Author(s): Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, et al.

Endothelial nitric oxide synthase gene is positively associated with essential hypertension

Author(s): Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, et al.

Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with severe preeclampsia

Author(s): Yoshimura T, Yoshimura M, Tabata A, Shimasaki Y, Nakayama M, et al.